Skip to main content

Month: April 2024

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis. The initial funding of up to USD 0.9 million will support the work until candidate nomination in the second half of 2024. Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project...

Continue reading

Dime Announces Expansion of Private and Commercial Bank With Deposit-Focused Group Hires

Dime Continues To Execute On Growth Plan HAUPPAUGE, N.Y., April 08, 2024 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (the “Company” or “Dime”) (NASDAQ: DCOM), the parent company of Dime Community Bank (the “Bank”), announced the hiring of six deposit-focused Groups from the former Signature Bank and its successor, Flagstar Bank. Collectively, the Groups managed several billion in deposits at predecessor institutions. Commenting on the new Group hires, Stuart H. Lubow, President and Chief Executive Officer of Dime, said, “Building upon the successes we had over the past year, we are excited to announce the addition of several deposit-focused Groups. Including the hires announced today, we have added more than twelve deposit-focused Groups over the past twelve months to capitalize on the disruption in our marketplace. The...

Continue reading

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024. The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences. OKYO...

Continue reading

GFG Extends Private Placement & Plans to Close Financing on or Before April 19, 2024

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES SASKATOON, Saskatchewan, April 08, 2024 (GLOBE NEWSWIRE) — Canada: GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announces that the Company has received approval from the TSX Venture Exchange to extend the closing of its previously announced non-brokered private placement financing (the “Offering”) (see news release dated February 22, 2024). The Company anticipates closing the financing on or before April 19, 2024. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities...

Continue reading

Vast announces Term Sheet to facilitate transmission access for Aurora Energy Precinct

SYDNEY, Australia, April 08, 2024 (GLOBE NEWSWIRE) — Vast Renewables Limited (Vast) (Nasdaq: VSTE) and 1414 Degrees Limited (ASX:14D), through their joint venture SiliconAurora Pty Ltd (SiliconAurora), today announced the signing of a term sheet (Term Sheet) with Vast Solar 1 Pty Ltd and OZ Minerals Services Pty Ltd (OZM), a subsidiary of BHP Group Limited (BHP), to enter into negotiations with OZM for a possible binding agreement (Agreement) by 30 September 2024 (which date can be extended by mutual consent) (Agreement Date) that would facilitate access for the initial stages of the Aurora Energy Precinct (the Precinct) to the ElectraNet owned Hill-to-Hill Transmission Line (H2H) near Port Augusta, South Australia. The Precinct is owned by SiliconAurora, which plans to develop a 140MW (2 hour) battery energy storage system (BESS)...

Continue reading

Rio2 Announces Receipt of RCA Resolution for the Fenix Gold Project & C$10 Million Private Placement

Not for distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) today announces that its Chilean subsidiary, Fenix Gold Limitada (“Fenix Gold”), has received the formal Resolución de Calificación Ambiental (Environmental Qualification Resolution, or RCA) for its Fenix Gold Project (the “Project”) located in the Maricunga Mineral Belt of the Atacama Region, Chile. The RCA has been issued following the approval of the Project’s Environmental Impact Assessment previously announced on December 20, 2023. The receipt of the RCA now allows Fenix Gold to advance permitting activities for the Project. There are four principal Sectorial Permits required before construction...

Continue reading

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Brings extensive experience in retinal and ophthalmology diseases MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024. Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team. Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- and post-launch initiatives for medicines in ophthalmology and retinal...

Continue reading

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons – and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments. This exclusive distribution builds upon the agreement Smith+Nephew announced for Japan in April 2023. Lynette Walter, NAVBIT’s CEO said, “We are absolutely delighted to expand our partnership with Smith+Nephew...

Continue reading

Churchill Downs Incorporated Closes on Sale of 49% of United Tote Company to the New York Racing Association, Inc.

LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN, “CDI,” or the “Company”) announced today that the Company closed on the sale of 49% of United Tote Company (“United Tote”), a wholly-owned subsidiary of CDI, to NYRA Content Management Solutions, LLC, a subsidiary of the New York Racing Association, Inc. (“NYRA”). About Churchill Downs Incorporated Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) has been creating extraordinary entertainment experiences for nearly 150 years, beginning with the company’s most iconic and enduring asset, the Kentucky Derby. Headquartered in Louisville, Kentucky, CDI has expanded through the development of live and historical racing entertainment venues, the growth of the TwinSpires horse racing online wagering business and the operation and development...

Continue reading

Premier Health Announces the Appointment of Bruno Morel as its New CTO

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as the Corporation’s new Chief Technology Officer, effective immediately. “We are very excited to have Bruno join Premier Health. His hiring follows our recent Canadian expansion and is one of the key catalysts of our technology roadmap. He will be an important member of the Corporation’s senior leadership team as we continue to expand and execute our growth strategy,” said Martin Legault, Chief Executive Officer. Bruno has over 20 years of experience building complex software and managing development and operation teams in fast developing technology companies. Over the years, he has developed an expertise in the definition...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.